Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating Structure and Enables Achievement of Adjusted
Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development SOUTH SAN FRANCISCO, Calif. , May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif. , May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025 . Recent Highlights: First quarter 2025 revenue of $40.8 million 45% reduction in
Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical
SOUTH SAN FRANCISCO, Calif. , April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025 , after market close. The company will host a conference call and webcast on the same day at 4:30
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: TD Cowen’s 45th Annual Healthcare Conference - March 3 rd – 5 th , 2025 Presenting on Monday, March 3,
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024 . Recent Highlights: Full Year 2024 pro forma combined revenue
SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025 , after market close. The company will host a conference call and webcast on
Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024 , at 9:45 a.m. PT . SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and expanded drug indications as well as the potential for shorter and smaller clinical trials SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
